Boston Scientific has proven itself to be a fierce competitor among three major cardiac device makers, with a track record of meaningful innovation and impressive operational chops. Even a prolonged ...

The 8-year data may hold value for TAVI—the newest Sapien valve uses the same tissue—but many other variables differ.

Thanks to healthcare reform, the hurdles to securing reimbursement and technology add-on payments have risen. Boston will need to invest more in clinical studies to demonstrate superiority of outcomes ...